Circulating tumor cells and survival in abiraterone‐ and enzalutamide‐treated patients with castration‐resistant prostate cancer

Circulating tumor cells and survival in abiraterone‐ and enzalutamide‐treated patients with... INTRODUCTIONWith nearly 410 000 diagnoses in Europe each year, prostate cancer remains the most commonly diagnosed cancer in men. Approximately 10‐20% of the patients will ultimately advance to lethal, metastatic castration‐resistant prostate cancer (mCRPC). A continued targeting of the androgen receptor (AR) signalling pathway has proven to be useful. This has led to the development and clinical validation of next generation androgen deprivation therapies, encompassing the CYP17 inhibitor abiraterone acetate, and the anti‐androgen enzalutamide. Due to shifts in reimbursement criteria, novel agents and guidelines in the treatment of CRPC, a heterogeneous landscape of patients exists with respect to the current clinical practice. Circulating tumor cell (CTC) enumeration using the CellSearch System demonstrated how CTCs are an accurate and independent predictor of survival in metastatic prostate cancer. Here, we reassessed the prognostic value of baseline CTC enumeration via a prospective, multicentre study in patients with mCRPC starting a new line of systemic therapy with either abiraterone acetate or enzalutamide. Next, we evaluated the association between survival and CTC changes relative to baseline CTC enumeration (ie, CTC dynamics) in patients who responded for at least 10‐12 weeks. Secondary objectives included the assessment of the relationship of CTCs with baseline prostate‐specific antigen (PSA), http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png The Prostate Wiley

Loading next page...
 
/lp/wiley/circulating-tumor-cells-and-survival-in-abiraterone-and-enzalutamide-8BgGbnzBR2
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0270-4137
eISSN
1097-0045
D.O.I.
10.1002/pros.23488
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONWith nearly 410 000 diagnoses in Europe each year, prostate cancer remains the most commonly diagnosed cancer in men. Approximately 10‐20% of the patients will ultimately advance to lethal, metastatic castration‐resistant prostate cancer (mCRPC). A continued targeting of the androgen receptor (AR) signalling pathway has proven to be useful. This has led to the development and clinical validation of next generation androgen deprivation therapies, encompassing the CYP17 inhibitor abiraterone acetate, and the anti‐androgen enzalutamide. Due to shifts in reimbursement criteria, novel agents and guidelines in the treatment of CRPC, a heterogeneous landscape of patients exists with respect to the current clinical practice. Circulating tumor cell (CTC) enumeration using the CellSearch System demonstrated how CTCs are an accurate and independent predictor of survival in metastatic prostate cancer. Here, we reassessed the prognostic value of baseline CTC enumeration via a prospective, multicentre study in patients with mCRPC starting a new line of systemic therapy with either abiraterone acetate or enzalutamide. Next, we evaluated the association between survival and CTC changes relative to baseline CTC enumeration (ie, CTC dynamics) in patients who responded for at least 10‐12 weeks. Secondary objectives included the assessment of the relationship of CTCs with baseline prostate‐specific antigen (PSA),

Journal

The ProstateWiley

Published: Jan 1, 2018

Keywords: ; ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from Google Scholar, PubMed
Create lists to organize your research
Export lists, citations
Access to DeepDyve database
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off